Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) Prevention of Relapse of Multiple Sclerosis
Not Applicable
Completed
- Conditions
- Multiple sclerosis
- Registration Number
- JPRN-jRCT1080223004
- Lead Sponsor
- TAKEDA PHARMACEUTICAL COMPANY LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 1332
Inclusion Criteria
All patients treated with Copaxone from the first day of market launch of the product
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of participants who had one or more adverse events<br><br>Timeframe; Up to 24 months <br>Annual relapse rate (ARR)<br>The annual relapse rate (ARR) after the start of treatment will be calculated throughout study.<br>Timeframe; Up to 24 months
- Secondary Outcome Measures
Name Time Method